Interstitial Cystitis (Hunner Lesions)

1. Executive Overview: Understanding Interstitial Cystitis with Hunner Lesions

Interstitial Cystitis (IC), also clinically classified under the umbrella of Bladder Pain Syndrome (BPS), is a chronic, debilitating condition characterized by suprapubic pain related to bladder filling, accompanied by other symptoms such as increased daytime and nighttime urinary frequency. When specifically categorized as Interstitial Cystitis with Hunner Lesions (IC-HL)—coded as ICD-10 N30.10—the condition represents a distinct, inflammatory subtype of the disease.

Unlike non-ulcerative IC, which often presents with a normal-appearing bladder mucosa, IC-HL is marked by the presence of Hunner lesions: circumscribed, inflammatory, erythematous mucosal areas that bleed upon bladder distention (glomerulation). These lesions are histologically distinct, characterized by chronic inflammatory infiltrates, mast cell activation, and a compromised urothelial barrier. Patients with Hunner lesions typically experience more severe symptoms, higher levels of pain, and a more significant impact on quality of life compared to those with non-ulcerative forms. This guide serves as a clinical resource for understanding the etiology, diagnosis, and evidence-based management of this complex urological pathology.

2. Pathophysiology, Etiology, and Risk Factors

The pathophysiology of Hunner lesion IC is multifactorial and remains a subject of intensive urological research. While the exact trigger is unknown, several key mechanisms are identified:

The Urothelial Barrier Defect

The bladder urothelium is protected by a glycosaminoglycan (GAG) layer that prevents urinary solutes (potassium, urea, toxins) from infiltrating the submucosa. In IC-HL, this barrier is markedly compromised. The resulting permeability allows urinary components to penetrate the urothelium, triggering a cascade of neurogenic inflammation, mast cell degranulation, and sensory nerve sensitization.

Neurogenic Inflammation and Mast Cells

Hunner lesions are characterized by a profound neuro-inflammatory response. Research indicates a significant increase in mast cell density in the suburothelial space. These cells release histamine, tryptase, and other pro-inflammatory cytokines, which stimulate sensory afferent nerves, leading to the chronic "pain-frequency" cycle.

Key Risk Factors and Associations

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of IC-HL is often progressive. Patients typically present with a constellation of symptoms that must persist for at least six weeks to satisfy diagnostic criteria.

Cardinal Symptoms

• Chronic Pelvic Pain: Described as aching, burning, or stabbing pain located in the suprapubic, pelvic, or perineal regions.
• Urinary Frequency: The need to void frequently, often exceeding 8–10 times per 24 hours.
• Urgency: A sudden, intense desire to void, which may or may not be associated with urge incontinence.
• Nocturia: Waking multiple times during the night to void, significantly disrupting sleep architecture.

The "Pain-Filling" Correlation

A hallmark of the condition is that pain intensity increases as the bladder fills and is usually relieved (at least temporarily) by micturition. This distinguishes IC-HL from other pelvic pain syndromes where pain may be constant regardless of bladder volume.

4. Standard Diagnostic Evaluation & Workup

Diagnosing IC-HL is a process of exclusion followed by direct visualization. Because symptoms overlap with urinary tract infections (UTIs), overactive bladder (OAB), and malignancy, a systematic approach is essential.

The Diagnostic Algorithm

1. Clinical History & Physical: Assessment of pain patterns, voiding diaries, and exclusion of pelvic floor dysfunction.
2. Urinalysis & Culture: Essential to rule out active bacterial infection.
3. Cystoscopy (The Gold Standard): Office-based or under anesthesia, cystoscopy is required to identify Hunner lesions. In patients with IC-HL, the lesions appear as red, velvet-like patches that often exhibit "waterfall bleeding" upon bladder distention.
4. Bladder Biopsy: While not always mandatory for diagnosis, biopsy is recommended to exclude malignancy (such as Carcinoma In Situ - CIS) and to confirm the presence of chronic inflammatory infiltrates characteristic of Hunner lesions.

Differential Diagnosis Table

5. Therapeutic Interventions

Management of IC-HL requires a multimodal, stepped-care approach. Because there is no "cure," the goal is symptom control and functional improvement.

First-Line Treatment

• Patient Education: Understanding the chronic nature and the role of trigger avoidance.
• Lifestyle Modification: Implementation of an "IC-friendly" diet (avoiding caffeine, alcohol, spicy foods, and artificial sweeteners).
• Stress Management: Pelvic floor physical therapy to address secondary muscle guarding.

Second-Line Pharmacotherapy

• Oral Pentosan Polysulfate Sodium (PPS): Known to help restore the GAG layer.
• Hydroxyzine: An antihistamine used to stabilize mast cells and reduce neurogenic inflammation.
• Amitriptyline: A tricyclic antidepressant used for its neuromodulatory and analgesic properties.

Third-Line and Surgical Interventions

• Intravesical Instillations: Direct delivery of DMSO, heparin, or lidocaine into the bladder to soothe the mucosa.
• Fulguration/Laser Ablation: For patients with biopsy-confirmed Hunner lesions, endoscopic fulguration (cauterization) or laser therapy of the lesions provides significant, albeit sometimes temporary, pain relief.
• Intralesional Triamcinolone: Injection of steroids directly into the lesion has shown efficacy in reducing inflammation and extending remission periods.

6. Frequently Asked Questions (FAQ)

1. Is Interstitial Cystitis a permanent condition?
Yes, it is considered a chronic, lifelong condition; however, with proper management, many patients achieve long periods of remission and significant symptom control.

2. How do I know if I have Hunner lesions versus non-ulcerative IC?
The only way to distinguish them is through cystoscopy. Hunner lesions are physically visible as inflammatory patches, whereas non-ulcerative IC does not show these specific mucosal lesions.

3. Does diet really affect my bladder pain?
For many patients, yes. Acidic foods, caffeine, and alcohol can irritate the sensitive bladder lining. Keeping a food diary is highly recommended.

4. Is surgery an option for IC-HL?
Major surgery (like cystectomy) is a last resort. However, endoscopic procedures like fulguration or laser therapy are standard, minimally invasive treatments for Hunner lesions.

5. Can IC lead to bladder cancer?
No, IC/BPS is not a precursor to bladder cancer. However, your doctor will perform tests to rule out cancer because the symptoms can be similar.

6. What is the role of pelvic floor physical therapy?
Many IC patients develop pelvic floor muscle spasms due to chronic pain. Physical therapy helps release these muscles, reducing the overall pelvic pain burden.

7. Are antibiotics effective for IC?
Only if you have a concurrent bacterial infection. IC is an inflammatory, not infectious, condition; therefore, antibiotics will not treat the underlying IC.

8. Can I have a normal life with this diagnosis?
Yes. Through a combination of lifestyle changes, medication, and, if necessary, procedural interventions, most patients maintain a high quality of life.

9. Why do my symptoms get worse during certain times of the month?
Hormonal fluctuations can influence bladder sensitivity and pain perception in many women with IC.

10. Is there a specific test to confirm IC?
There is no single "blood test" for IC. It remains a diagnosis of exclusion combined with clinical findings and cystoscopic evidence for those with Hunner lesions.